Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isoniazid (BridgeBio Pharma)
- Development stage
- Unknown
- Lead developer
- Bridge BioResearch
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BBR-012 is an oral small molecule formulation of the antimicrobial agent isoniazid, developed by Bridge BioResearch Rights (Jersey) Ltd for the treatment of diabetic foot ulcers (DFU). While isoniazid is traditionally used as a first-line treatment for tuberculosis, BBR-012 explores its potential to accelerate wound healing in ischaemic or neuro-ischaemic foot ulcers through the inhibition of cytochrome P450 (CYP) enzymes. The drug was evaluated in a Phase IIa proof-of-concept trial (NCT01342497) in the United Kingdom, where it was administered alongside standard medical care. However, the clinical development for this indication was terminated due to recruitment challenges.
- Other names
- isoniazidisoniazide
02
Targets
CYP2C19 (Cytochrome P450 2C19)CYP1A2 (Cytochrome P450 1A2)CYP3A4 (Cytochrome P450 3A4)CYP2A6 (Cytochrome P450 2A6)CYP2E1InhA
Beyond the preview
Go deeper on isoniazid (BridgeBio Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isoniazid (BridgeBio Pharma).